Sbarra, David A. http://orcid.org/0000-0001-6727-6552
Ramadan, Ferris A.
Choi, Karmel W.
Treur, Jorien L.
Levey, Daniel F. http://orcid.org/0000-0001-8431-9569
Wootton, Robyn E. http://orcid.org/0000-0003-3961-3202
Stein, Murray B. http://orcid.org/0000-0001-9564-2871
Gelernter, Joel http://orcid.org/0000-0002-4067-1859
Klimentidis, Yann C.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG078361-01)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (K08MH127413)
Article History
Received: 22 November 2022
Revised: 6 September 2023
Accepted: 8 September 2023
First Online: 21 September 2023
Competing interests
: MBS in the past 3 years has received consulting income from Actelion, Acadia Pharmaceuticals, Aptinyx, Bionomics, BioXcel Therapeutics, Clexio, EmpowerPharm, GW Pharmaceuticals, Janssen, Jazz Pharmaceuticals, and Roche/Genentech. He has also received research support from NIH, Department of Veterans Affairs, and the Department of Defense. He is on the scientific advisory board for Brain and Behavior Research Foundation and the Anxiety and Depression Association of America. Dr. Stein has stock options in Oxeia Biopharmaceuticals and Epivario.